Nanotechnology in ovarian cancer: Diagnosis and treatment
Mahmood Barania, Muhammad Bilalb, Fakhara Sabirc, Abbas Rahdard e✉, George Z. Kyzasf g✉
- aDepartment of Chemistry, Shahid Bahonar University of Kerman, Kerman, Iran
- bSchool of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China
- cUniversity of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, H-6720 Szeged, Eötvös u. 6, Hungary
- dDepartment of Physics, University of Zabol, 98613-35856 Zabol, Iran. Electronic address: a.rahdar@uoz.ac.ir
- eDepartment of Physics, University of Zabol, 98613-35856 Zabol, Iran
- fDepartment of Chemistry, International Hellenic University, Kavala, Greece. Electronic address: kyzas@chem.ihu.gr
- gDepartment of Chemistry, International Hellenic University, Kavala, Greece
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
To overcome the drawbacks of conventional delivery, this review spotlights a number of nanoscale drug delivery systems, including nanoparticles, liposomes, nano micelles, branched dendrimers, nanocapsules, and nanostructured lipid formulations for the targeted therapy of ovarian cancer. These nanoformulations offer numerous advantages to promote therapeutic drug delivery such as nontoxicity, biocompatibility, good biodegradability, increased therapeutic impact than free drugs, and non-inflammatory effects. Importantly, the development of specific ligands functionalized nanoformulations enable preferential targeting of ovarian tumors and eventually amplify the therapeutic potential compared to nonfunctionalized counterparts. Ovarian cancer is typically identified by biomarker assessment such as CA125, HE4, Mucin 1, and prostatic. There is, nevertheless, a tremendous demand for less costly, faster, and compact medical tools, both for timely detection and ovarian cancer control. This paper explored multiple types of tumor marker-based on nanomaterial biosensors. Initially, we mention different forms of ovarian cancer biomarkers involving CA125, human epididymis protein 4 (HE4), mucin 1 (MUC1), and prostate. It is accompanied by a brief description of new nanotechnology methods for diagnosis. Nanobiosensors for evaluating ovarian cancer biomarkers can be categorized based on electrochemical, optical, paper-based, giant magnetoresistive, and lab-on-a-chip devices.
TL;DRA number of nanoscale drug delivery systems, including nanoparticles, liposomes, nano micelles, branched dendrimers, nanocapsules, and nanostructured lipid formulations for the targeted therapy of ovarian cancer are reviewed to overcome the drawbacks of conventional delivery. (Semantic Scholar)